english.prescrire.org > Prescrire International > N°131 - October 2012

n°131

October 2012

Issue Contents
Editorial

Free  Common sense

p.228
Irrational approval of asenapine

New Products


Asenapine (New Drug)

p.229-232
A less effective, yet more dangerous, neuroleptic!

Vandetanib (New Drug)

p.233
Too dangerous in medullary thyroid cancer

Everolimus 10 mg and pancreatic neuroendocrine tumours (New Indication)

p.234
Many adverse effects and uncertain benefit

Ritonavir oral solution (New Dosing Device)

p.235
Still graduated in ml in the EU

INN common stem: -peridone

p.235

Adverse Effects


Accidental injection with adrenaline autoinjectors

p.236-239
Poor knowledge of use and design flaws

Prescrire's advice

p.238
Preventing unintentional adrenaline injection with autoinjectors

Topical tacrolimus: cancers (continued)

p.239
Lymphomas and carcinomas

Venlafaxine and quetiapine bezoars

p.239
Prolonged symptoms of overdose

Free  Nicorandil: mucocutaneous ulceration (continued)

p.240
A very severe case report

Free  Varenicline and bupropion: suicide

p.240
An analysis of reports in the USA

Free  Venlafaxine: preeclampsia and eclampsia

p.240
Gestational hypertension

Free  Benfluorex: lesions on a bioprosthetic heart valve too

p.240-241
A troubling case report

SSRI antidepressants: persistent pulmonary hypertension in newborns (continued)

p.241
Consistent data

Methylphenidate: abuse and addiction

p.241
In young adults and adolescents

Pelargonium: severe liver damage

p.241
Harmful plants

Reviews


Management of localised prostate cancer

p.242-248
Watchful waiting, surgery or radiation therapy

Reducing adverse effects of treatments for prostate cancer

p.245

Prescrire's advice

p.247
Treatment of localised prostate cancer: inform patients about adverse effects

Immediate IUD insertion after abortion

p.248
A safe option

Homeopathy: still no evidence of efficacy

p.248
Belgian health technology assessment

Outlook


Free  Packaging of medicines for paediatric use: Prescrire's constructive proposals

p.249-250
A response to the European Medicines Agency

Free  Pharmaceutical companies: safe stock market investments

p.251
Profits not dependent on therapeutic advance

Masthead


Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe